Skip to main content
    L

    Lantern Pharma Inc (LTRN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    -0.04 (-10.18%)

    Market Cap: $6.47M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Lantern Pharma Inc (LTRN) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    Lantern Pharma reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$17.12M, operating cash flow was -$15.68M and free cash flow was -$15.68M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$7.07M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $17.98M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Cost of revenue$0$0$0$0$0$0$0-$2.54K
    Gross profit$0$0$0$0$0$0$0$2.54K
    Research and development$11.51M$16.13M$11.89M$8.60M$7.57M$2.24M$953.18K$572.10K
    Operating income-$17.98M-$22.22M-$17.88M-$14.43M-$12.59M-$5.91M-$2.43M-$1.73M
    Net income-$17.12M-$20.78M-$15.96M-$14.26M-$12.36M-$5.91M-$2.43M-$1.73M
    EBITDA-$17.74M-$21.74M-$16.89M-$14.37M-$12.28M-$5.90M-$2.43MN/A
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$100.65K$0$0$0$261.05K$0
    Gross profit$0$0$4.10K$0$0$0-$51.22K$0$0$0-$44.32K$0
    Operating income-$3.51M-$3.41M-$4.20M-$4.35M-$4.65M-$4.77M-$5.90M-$5.18M-$5.41M-$5.73M-$4.88M-$3.52M
    Net income-$7.07M-$3.33M-$4.07M-$4.18M-$4.33M-$4.54M-$5.88M-$4.51M-$4.96M-$5.44M-$4.19M-$3.16M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $78.54M exceeded cash and equivalents by $74.12M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$11.04M$25.57M$43.65M$58.84M$73.95M$20.36M$1.43M$449.83K
    Current assets$10.80M$25.25M$43.34M$58.72M$72.72M$20.24M$1.23M$445.16K
    Cash and equivalents$4.42M$7.51M$21.94M$37.20M$51.52M$19.23M$1.23M$445.16K
    Total liabilities$4.50M$4.38M$2.74M$2.80M$2.38M$660.84K$489.29K$651.63K
    Short-term debt$78.54M$190.81K$172.97K$52.89K$152.06KN/AN/AN/A
    Long-term debtN/AN/AN/AN/AN/A$108.50KN/AN/A
    Shareholder equity$6.53M$21.19M$40.91M$56.04M$71.57M$19.70M$943.28K-$201.80K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$8.60M$7.22M$11.04M$13.63M$17.42M$21.10M$25.57M$30.29M$35.59M$39.73M$43.65M$47.77M
    Total liabilities$11.82M$3.78M$4.50M$4.04M$4.90M$4.32M$4.38M$3.70M$4.66M$3.97M$2.74M$2.36M
    Cash and equivalents$6.66M$4.92M$4.42M$8.39M$6.06M$6.38M$7.51M$8.10M$12.98M$18.36M$21.94M$25.57M
    Shareholder equity-$3.22M$3.45M$6.53M$9.59M$12.52M$16.78M$21.19M$26.60M$30.93M$35.77M$40.91M$45.41M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$15.68M-$17.81M-$14.35M-$12.77M-$10.59M-$5.65M-$2.13M-$1.27M
    Capital expenditures$1.72K$12.60K$18.73K$27.84K$15.50K$16.14K$5.72K$5.72K
    Free cash flow-$15.68M-$17.83M-$14.37M-$12.80M-$10.61M-$5.67M-$2.13M-$1.28M
    Share repurchases$139.75K$0$500.00K$2.48M$5.72M$0N/AN/A
    Investing cash flow$11.06M$3.37M-$930.21K$179.27K-$19.53M-$16.14K-$5.72K$5.34K
    Financing cash flow$1.50M$66.71K-$500.00K-$2.18M$63.42M$23.66M$2.92M$535.00K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$2.94M-$3.77M-$2.79M-$4.57M-$3.94M-$4.38M-$3.97M-$5.58M-$5.19M-$3.07M-$3.39M-$3.61M
    Capital expendituresN/A$0$1$555$3$1.16K$3.08K$3.03K$4.27K$2.22K$5.08K$4.78K
    Free cash flowN/A-$3.77M-$2.79M-$4.57M-$3.94M-$4.38M-$3.97M-$5.59M-$5.19M-$3.07M-$3.39M-$3.62M
    Last 12 quarters

    Frequently Asked Questions About LTRN

    What is Lantern Pharma's annual revenue?

    Lantern Pharma reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Lantern Pharma profitable?

    No. Lantern Pharma reported net income of -$17.12M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does LTRN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$15.68M minus capital expenditures of $1.72K produced free cash flow of -$15.68M.

    How much debt does Lantern Pharma have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $78.54M and cash and equivalents of $4.42M.